Evidence mapPaperPMID 39822337Full record

ArticleJournal of the Saudi Heart Association2024

A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus.

Waleed Alhabeeb, Abdelfatah Elasfar, Abdulhalim J Kinsara, Ahmed Aljizeeri, Ibrahim Jelaidan, Kamal Alghalayini, Mohammed F AlKheraiji, Mousa Akbar, Sameh Lawand, Sarah M Alyousif and 2 more

Abstract read
In one paragraph

Article in Journal of the Saudi Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Waleed AlhabeebDepartment of Cardiac Sciences, King Saud University, Riyadh, Saudi Arabia.
Abdelfatah ElasfarCardiology Department, Hamad Medical Corporation, Qatar.
Abdulhalim J KinsaraMinistry of National Guard Health Affairs, Jeddah, Saudi Arabia.
Ahmed AljizeeriKing Abdulaziz Cardiac Center, Ministry of the National Guard Health Affairs, Riyadh, Saudi Arabia.
Ibrahim JelaidanMinistry of National Guard Health Affairs, Jeddah, Saudi Arabia.
Kamal AlghalayiniKing Abdulaziz University Hospital, Jeddah, Saudi Arabia.
Mohammed F AlKheraijiRiyadh First Health Cluster - Ministry of Health, Riyadh, Saudi Arabia.
Mousa AkbarAl-Sabah Hospital, Ministry of Health, Kuwait.
Sameh LawandSenior Consultant Interventional Cardiologist at Dallah Hospital, Riyadh, Saudi Arabia.
Sarah M AlyousifAl-Sabah Hospital, Ministry of Health, Kuwait.
Saud AlsifriEndocrinology Department, Alhada Armed Forces Hospital, Taif, Saudi Arabia.
Taher HassanBugshan Center, Jeddah, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cardiovascular disease (CVD) and diabetes mellitus are prominent public health concerns in Saudi Arabia owing to their increasingly high prevalence and burden. Based on this, the Saudi Heart Association (SHA) set out to develop an official position statement on CVD and diabetes mellitus, with a focus on the prevention and management of these conditions and relevant special populations in the context of Saudi Arabia. Methods: A multidisciplinary panel of experts met under the auspices of the SHA in a series of meetings to review and discuss available evidence on the prevention and management of comorbid CVD and diabetes mellitus. Specialized subcommittees reviewed the data and offered context-specific recommendations (taking into account Saudi population characteristics, local healthcare system, available resources and medical expertise), which were later approved by the full expert panel. Results and conclusions: The prevalence of diabetes mellitus and CVD is alarming in the Saudi Arabian population. Diabetes mellitus and CVD are interconnected on several levels, including cellular and molecular events as well as epigenetic and genetic mechanisms. Screening for CVD is a priority for patients with diabetes and concomitant risk factors. The expert panel also recommends aggressive management of high blood pressure and dyslipidemia in addition to lifestyle changes and achieving glycemic targets for the prevention of CVD in patients with diabetes. Some glucose-lowering drug classes, namely SGLT2-inhibitors and GLP-1 receptor agonists, offer significant benefits on the level of cardiovascular risk reduction and are thus a powerful addition to the clinical management armamentarium in CVD and diabetes. Special consideration is also advised for patient populations with distinct clinical presentation and needs, such as coronary artery disease, heart failure, and chronic kidney disease, among others.

Indexed as

Cardiovascular diseasesDiabetesDisease managementSaudi Arabia

Identifiers

PMID39822337
PMCPMC11737320

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.